SPRY1, an inhibitor of the Ras-MAPK pathway, can interact with uPAR and promote its lysosomal-mediated degradation, resulting in inhibition of the activation of the FAK and ERK pathways, which suppresses the tumor proliferation induced by uPAR 73-75. Here, PLAUR is linked to neoplasm.